Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short term Debt: 2009-2025

Historic Short term Debt for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $9.1 million.

  • Aytu Biopharma's Short term Debt rose 248.31% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 248.31%. This contributed to the annual value of $9.1 million for FY2025, which is 278.41% up from last year.
  • Latest data reveals that Aytu Biopharma reported Short term Debt of $9.1 million as of FY2025, which was up 278.41% from $2.4 million recorded in FY2024.
  • Aytu Biopharma's Short term Debt's 5-year high stood at $16.7 million during FY2021, with a 5-year trough of $1.6 million in FY2023.
  • Moreover, its 3-year median value for Short term Debt was $2.4 million (2024), whereas its average is $4.3 million.
  • In the last 5 years, Aytu Biopharma's Short term Debt surged by 1,597.35% in 2021 and then plummeted by 77.12% in 2022.
  • Aytu Biopharma's Short term Debt (Yearly) stood at $16.7 million in 2021, then tumbled by 77.12% to $3.8 million in 2022, then crashed by 59.01% to $1.6 million in 2023, then spiked by 53.23% to $2.4 million in 2024, then spiked by 278.41% to $9.1 million in 2025.